Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm

Free Radical Biology and Medicine

Volumn 91, Issue , 2016, Pages 127-142

  Barone, Eugenio ^a,b   Di Domenico, Fabio ^a   Cassano, Tommaso ^c   Arena, Andrea ^a   Tramutola, Antonella ^a   Lavecchia, Michele Angelo ^a   Coccia, Raffaella ^a   Butterfield, D Allan ^d   Perluigi, Marzia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

3xTg AD mice; Alzheimer disease; Biliverdin reductase A; Insulin resistance; Oxidative stress

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; AMYLOID BETA PROTEIN; BILIVERDIN REDUCTASE A; CARBONYL DERIVATIVE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OXIDOREDUCTASE; PROTEIN CARBONYL; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BILIVERDIN REDUCTASE; TARGET OF RAPAMYCIN KINASE; TUMOR NECROSIS FACTOR;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN TREATMENT; LONGITUDINAL STUDY; MALE; MOUSE; NEUROBLASTOMA CELL; NITRATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; 129 MOUSE; ANIMAL; C57BL MOUSE; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PROTEIN PROCESSING; TRANSGENIC MOUSE; TUMOR CELL LINE;

AGING; ALZHEIMER DISEASE; ANIMALS; CELL LINE, TUMOR; HIPPOCAMPUS; HUMANS; INSULIN RESISTANCE; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDATIVE STRESS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84950335909     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2015.12.012     Document Type: Article

References (74)

1. S.M. de la Monte, and M. Tong Brain metabolic dysfunction at the core of Alzheimer's disease Biochem. Pharmacol. 88 2014 548 559
2. F.G. De Felice Alzheimer's disease and insulin resistance: translating basic science into clinical applications J. Clin. Investig. 123 2013 531 539
3. A. Ott, R.P. Stolk, F. van Harskamp, H.A. Pols, A. Hofman, and M.M. Breteler Diabetes mellitus and the risk of dementia: The Rotterdam Study Neurology 53 1999 1937 1942
4. P.K. Crane, R. Walker, and E.B. Larson Glucose levels and risk of dementia New. Engl. J. Med. 369 2013 1863 1864
5. A.A. Willette, B.B. Bendlin, E.J. Starks, A.C. Birdsill, S.C. Johnson, B.T. Christian, O.C. Okonkwo, A. La Rue, B.P. Hermann, R.L. Koscik, E.M. Jonaitis, M.A. Sager, and S. Asthana Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease JAMA Neurol. 72 2015 1013 1020
6. J. Janson, T. Laedtke, J.E. Parisi, P. O'Brien, R.C. Petersen, and P.C. Butler Increased risk of type 2 diabetes in Alzheimer disease Diabetes 53 2004 474 481
7. S. Craft Alzheimer disease: Insulin resistance and AD - extending the translational path Nat. Rev. Neurol. 8 2012 360 362
8. R. Ghasemi, A. Haeri, L. Dargahi, Z. Mohamed, and A. Ahmadiani Insulin in the brain: sources, localization and functions Mol. Neurobiol. 47 2013 145 171
9. K. Talbot, H.Y. Wang, H. Kazi, L.Y. Han, K.P. Bakshi, A. Stucky, R.L. Fuino, K.R. Kawaguchi, A.J. Samoyedny, R.S. Wilson, Z. Arvanitakis, J.A. Schneider, B.A. Wolf, D.A. Bennett, J.Q. Trojanowski, and S.E. Arnold Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline J. Clin. Investig. 122 2012 1316 1338
10. E. Blazquez, E. Velazquez, V. Hurtado-Carneiro, and J.M. Ruiz-Albusac Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease Front. Endocrinol. 5 2014 161
11. J.M. Horwood, F. Dufour, S. Laroche, and S. Davis Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat Eur. J. Neurosci. 23 2006 3375 3384
12. V. Calabrese, C. Mancuso, M. Calvani, E. Rizzarelli, D.A. Butterfield, and A.M. Stella Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity Nat. Rev. Neurosci. 8 2007 766 775
13. K. Akter, E.A. Lanza, S.A. Martin, N. Myronyuk, M. Rua, and R.B. Raffa Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br. J. Clin. Pharmacol. 71 2011 365 376
14. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, X.J. Xu, J.R. Wands, and S.M. de la Monte Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J. Alzheimer's Dis.: Jad. 7 2005 63 80
15. E.J. Rivera, A. Goldin, N. Fulmer, R. Tavares, J.R. Wands, and S.M. de la Monte Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine J. Alzheimer's Dis.: Jad. 8 2005 247 268
16. F.G. De Felice, M.N. Vieira, T.R. Bomfim, H. Decker, P.T. Velasco, M.P. Lambert, K.L. Viola, W.Q. Zhao, S.T. Ferreira, and W.L. Klein Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers Proc. Natl. Acad. Sci. United S. Am. 106 2009 1971 1976
17. T.R. Bomfim, L. Forny-Germano, L.B. Sathler, J. Brito-Moreira, J.C. Houzel, H. Decker, M.A. Silverman, H. Kazi, H.M. Melo, P.L. McClean, C. Holscher, S.E. Arnold, K. Talbot, W.L. Klein, D.P. Munoz, S.T. Ferreira, and F.G. De Felice An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers J. Clin. Investig. 122 2012 1339 1353
18. M.V. Lourenco, J.R. Clarke, R.L. Frozza, T.R. Bomfim, L. Forny-Germano, A.F. Batista, L.B. Sathler, J. Brito-Moreira, O.B. Amaral, C.A. Silva, L. Freitas-Correa, S. Espirito-Santo, P. Campello-Costa, J.C. Houzel, W.L. Klein, C. Holscher, J.B. Carvalheira, A.M. Silva, L.A. Velloso, D.P. Munoz, S.T. Ferreira, and F.G. De Felice TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys Cell. Metab. 18 2013 831 843
19. K.D. Copps, and M.F. White Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 Diabetologia 55 2012 2565 2582
20. E. Barone, F. Di Domenico, G. Cenini, R. Sultana, R. Coccia, P. Preziosi, M. Perluigi, C. Mancuso, and D.A. Butterfield Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment J. Alzheimer's Dis.: Jad. 25 2011 623 633
21. E. Barone, F. Di Domenico, G. Cenini, R. Sultana, C. Cini, P. Preziosi, M. Perluigi, C. Mancuso, and D.A. Butterfield Biliverdin reductase - a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment Biochim. Et. Biophys. Acta 1812 2011 480 487
22. N. Lerner-Marmarosh, J. Shen, M.D. Torno, A. Kravets, Z. Hu, and M.D. Maines Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity Proc. Natl. Acad. Sci. U.S.A. 102 2005 7109 7114
23. B. Wu, X. Liu, and J. Shen Old biliverdin reductase: links to insulin resistance and may be a novel therapeutic target Med. Hypotheses 71 2008 73 76
24. J. Kapitulnik, and M.D. Maines Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin Trends Pharmacol. Sci. 30 2009 129 137
25. R. Stocker Antioxidant activities of bile pigments Antioxid. Redox Signal 6 2004 841 849
26. E. Barone, S. Trombino, R. Cassano, A. Sgambato, B. De Paola, E. Di Stasio, N. Picci, P. Preziosi, and C. Mancuso Characterization of the S-denitrosylating activity of bilirubin J. Cell. Mol. Med. 13 2009 2365 2375
27. P.E. Gibbs, N. Lerner-Marmarosh, A. Poulin, E. Farah, and M.D. Maines Human biliverdin reductase-based peptides activate and inhibit glucose uptake through direct interaction with the kinase domain of insulin receptor FASEB J. 28 2014 2478 2491
28. E. Barone, F. Di Domenico, C. Mancuso, and D.A. Butterfield The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation Neurobiol. Dis. 62 2014 144 159
29. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari, and F.M. LaFerla Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction Neuron 39 2003 409 421
30. T. Cassano, A. Romano, T. Macheda, R. Colangeli, C.S. Cimmino, A. Petrella, F.M. LaFerla, V. Cuomo, and S. Gaetani Olfactory memory is impaired in a triple transgenic model of Alzheimer disease Behav. Brain Res. 224 2011 408 412
31. A. Romano, L. Pace, B. Tempesta, A.M. Lavecchia, T. Macheda, G. Bedse, A. Petrella, C. Cifani, G. Serviddio, G. Vendemiale, S. Gaetani, and T. Cassano Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease Int. J. Neuropsychopharmacol. 18 2015
32. T. Cassano, G. Serviddio, S. Gaetani, A. Romano, P. Dipasquale, S. Cianci, F. Bellanti, L. Laconca, A.D. Romano, I. Padalino, F.M. LaFerla, F. Nicoletti, V. Cuomo, and G. Vendemiale Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease Neurobiol. aging 33 2012 e1121 1122
33. C.M. Mayer, and D.D. Belsham Central insulin signaling is attenuated by long-term insulin exposure via insulin receptor substrate-1 serine phosphorylation, proteasomal degradation, and lysosomal insulin receptor degradation Endocrinology 151 2010 75 84
34. G. Cenini, R. Sultana, M. Memo, and D.A. Butterfield Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease Free. Radic. Biol. Med. 45 2008 81 85
35. M. Salim, B.A. Brown-Kipphut, and M.D. Maines Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation J. Biol. Chem. 276 2001 10929 10934
36. N. Lerner-Marmarosh, T. Miralem, P.E. Gibbs, and M.D. Maines Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling Proc. Natl. Acad. Sci. U.S.A. 105 2008 6870 6875
37. F. Di Domenico, E. Barone, C. Mancuso, M. Perluigi, A. Cocciolo, P. Mecocci, D.A. Butterfield, and R. Coccia HO-1/BVR-a system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease J. Alzheimer's Dis.: Jad. 32 2012 277 289
38. S. Oddo, A. Caccamo, B. Tseng, D. Cheng, V. Vasilevko, D.H. Cribbs, and F.M. LaFerla Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology J. Neurosci. 28 2008 12163 12175
39. P.E. Gibbs, T. Miralem, and M.D. Maines Characterization of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF-alpha-activated NF-kappaB FASEB J. 24 2010 3239 3254
40. M.C. Janelsins, M.A. Mastrangelo, S. Oddo, F.M. LaFerla, H.J. Federoff, and W.J. Bowers Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice J. Neuroinflammation 2 2005 23
41. S. Zaheer, R. Thangavel, Y. Wu, M.M. Khan, D. Kempuraj, and A. Zaheer Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice Neurochem. Res. 38 2013 218 225
42. C.J. Carlson, M.F. White, and C.M. Rondinone Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation Biochem. Biophys. Res. Commun. 316 2004 533 539
43. M. Perluigi, G. Pupo, A. Tramutola, C. Cini, R. Coccia, E. Barone, E. Head, D.A. Butterfield, and F. Di Domenico Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain Biochim. Et. Biophys. Acta 1842 2014 1144 1153
44. A. Tramutola, J.C. Triplett, F. Di Domenico, D.M. Niedowicz, M.P. Murphy, R. Coccia, M. Perluigi, and D.A. Butterfield Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD J. Neurochem. 133 2015 739 749
45. A. Caccamo, S. Majumder, A. Richardson, R. Strong, and S. Oddo Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments J. Biol. Chem. 285 2010 13107 13120
46. A. Caccamo, M.A. Maldonado, S. Majumder, D.X. Medina, W. Holbein, A. Magri, and S. Oddo Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism J. Biol. Chem. 286 2011 8924 8932
47. S. Oddo The role of mTOR signaling in Alzheimer disease Front Biosci. 4 2012 941 952
48. J. Bove, M. Martinez-Vicente, and M. Vila Fighting neurodegeneration with rapamycin: mechanistic insights Nat. Rev. Neurosci. 12 2011 437 452
49. D.N. Tripathi, R. Chowdhury, L.J. Trudel, A.R. Tee, R.S. Slack, C.L. Walker, and G.N. Wogan Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1 Proc. Natl. Acad. Sci. U.S.A. 110 2013 E2950 E2957
50. F.G. De Felice, M.V. Lourenco, and S.T. Ferreira How does brain insulin resistance develop in Alzheimer's disease? Alzheimer's Dement.: J. Alzheimer's Assoc. 10 2014 S26 S32
51. B. Cholerton, L.D. Baker, and S. Craft Insulin, cognition, and dementia Eur. J. Pharmacol. 719 2013 170 179
52. G. Bedse, F. Di Domenico, G. Serviddio, and T. Cassano Aberrant insulin signaling in Alzheimer's disease: current knowledge Front. Neurosci. 9 2015 204
53. Q.L. Ma, F. Yang, E.R. Rosario, O.J. Ubeda, W. Beech, D.J. Gant, P.P. Chen, B. Hudspeth, C. Chen, Y. Zhao, H.V. Vinters, S.A. Frautschy, and G.M. Cole Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin J. Neurosci. 29 2009 9078 9089
54. D.A. Butterfield, F. Di Domenico, and E. Barone Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain Biochim. Et. Biophys. Acta 1842 2014 1693 1706
55. S. Corrao, P. Santalucia, C. Argano, C.D. Djade, E. Barone, M. Tettamanti, L. Pasina, C. Franchi, T. Kamal Eldin, A. Marengoni, F. Salerno, M. Marcucci, P.M. Mannucci, A. Nobili, and R. Investigators Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study Eur. J. Intern. Med. 25 2014 617 623
56. R. Medeiros, M.A. Chabrier, and F.M. LaFerla Elucidating the triggers, progression, and effects of Alzheimer's disease J. Alzheimer's Dis.: Jad. 33 Suppl 1 2013 S195 S210
57. R. Gozzelino, V. Jeney, and M.P. Soares Mechanisms of cell protection by heme oxygenase-1 Annu. Rev. Pharmacol. Toxicol. 50 2010 323 354
58. J.F. Ewing, C.M. Weber, and M.D. Maines Biliverdin reductase is heat resistant and coexpressed with constitutive and heat shock forms of heme oxygenase in brain J. Neurochem. 61 1993 1015 1023
59. H.P. Monteiro Signal transduction by protein tyrosine nitration: competition or cooperation with tyrosine phosphorylation-dependent signaling events? Free. Radic. Biol. Med. 33 2002 765 773
60. D.A. Butterfield, and E.R. Stadman Protein oxidation processes in aging brain S.T. Paula, E.E. Bittar, Advances in Cell Aging and Gerontology 1997 161 191
61. H. Sancheti, I. Patil, K. Kanamori, R. Diaz Brinton, W. Zhang, A.L. Lin, and E. Cadenas Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a 13C NMR study J. Cereb. blood Flow. Metab. 34 2014 1749 1760
62. M. Vandal, P.J. White, G. Chevrier, C. Tremblay, I. St-Amour, E. Planel, A. Marette, and F. Calon Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease FASEB J. 29 2015 4273 4284
63. H. Sancheti, G. Akopian, F. Yin, R.D. Brinton, J.P. Walsh, and E. Cadenas Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease PLOS One 8 2013 e69830
64. R.M. Nicholson, Y. Kusne, L.A. Nowak, F.M. LaFerla, E.M. Reiman, and J. Valla Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models Brain Res. 1347 2010 179 185
65. J. Jurcovicova Glucose transport in brain-effect of inflammation Endocr. Regul. 48 2014 35 48
66. A. Klip The many ways to regulate glucose transporter 4 Appl. Physiol., Nutr., Metab. 34 2009 481 487
67. R. Nistico, V. Cavallucci, S. Piccinin, S. Macri, M. Pignatelli, B. Mehdawy, F. Blandini, G. Laviola, D. Lauro, N.B. Mercuri, and M. D'Amelio Insulin receptor beta-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory Neuromolecular Med. 14 2012 262 269
68. L.P. van der Heide, A. Kamal, A. Artola, W.H. Gispen, and G.M. Ramakers Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner J. Neurochem. 94 2005 1158 1166
69. M.W. Schwartz, D.F. Figlewicz, S.E. Kahn, D.G. Baskin, M.R. Greenwood, and D. Porte Jr. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats Peptides 11 1990 467 472
70. B.J. Wallum, G.J. Taborsky Jr., D. Porte Jr., D.P. Figlewicz, L. Jacobson, J.C. Beard, W.K. Ward, and D. Dorsa. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man J. Clin. Endocrinol. Metab. 64 1987 190 194
71. M. Belanger, I. Allaman, and P.J. Magistretti Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation Cell. Metab. 14 2011 724 738
72. A.M. Iyer, J. van Scheppingen, I. Milenkovic, J.J. Anink, H. Adle-Biassette, G.G. Kovacs, and E. Aronica mTOR Hyperactivation in down syndrome hippocampus appears early during development J. Neuropathol. Exp. Neurol. 73 2014 671 683
73. K. Bisht, B. Wegiel, J. Tampe, O. Neubauer, K.H. Wagner, L.E. Otterbein, and A.C. Bulmer Biliverdin modulates the expression of C5aR in response to endotoxin in part via mTOR signaling Biochem. Biophys. Res. Commun. 449 2014 94 99
74. S. Craft, L.D. Baker, T.J. Montine, S. Minoshima, G.S. Watson, A. Claxton, M. Arbuckle, M. Callaghan, E. Tsai, S.R. Plymate, P.S. Green, J. Leverenz, D. Cross, and B. Gerton Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial Arch. Neurol. 69 2012 29 38